ChemoMetec A/S (CPH:CHEMM)

Denmark · Delayed Price · Currency is DKK

318.80

-9.40 (-2.86%)

Apr 28, 2026, 4:59 PM CET

-31.62% (1Y)

Market Cap	5.55B
Revenue (ttm)	493.12M
Net Income (ttm)	177.03M
Shares Out	17.40M
EPS (ttm)	10.17
PE Ratio	31.35
Forward PE	26.31
Dividend	7.00 (2.13%)
Ex-Dividend Date	Oct 10, 2025

Volume	70,285
Average Volume	78,473
Open	328.20
Previous Close	328.20
Day's Range	317.00 - 328.60
52-Week Range	235.20 - 804.00
Beta	1.36
RSI	41.81
Earnings Date	Sep 10, 2026

About ChemoMetec

ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in the areas of cell and gene therapy, cancer and stem cell research, and development and manufacturing of pharmaceuticals, as well as production and quality control of animal semen, milk, and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202... [Read more]

Industry Medical Devices

Sector Healthcare

Founded 1997

Employees 172

Stock Exchange Copenhagen Stock Exchange

Ticker Symbol CHEMM

Full Company Profile

Financial Performance

In fiscal year 2025, ChemoMetec's revenue was 495.57 million, an increase of 21.50% compared to the previous year's 407.87 million. Earnings were 186.41 million, an increase of 36.78%.

Financial Statements

News

ChemoMetec Earnings Call Transcript: Q1 2026

Revenue grew 8% year-over-year with strong XM platform adoption and improved margins. Upgraded guidance reflects broad customer interest, with larger XM orders expected by fiscal year-end. Strategic focus is on software and automation, supporting long-term profitability.

6 months ago - Transcripts

Full Year 2025 Chemometec A/S Earnings Call Transcript

6 months ago - GuruFocus

ChemoMetec Earnings Call Transcript: Q4 2025

Revenue, EBITDA, and cash flow increased year-over-year, with strong growth across all segments and a high gross margin. Guidance anticipates 10–14% sales growth, margin improvement, and major investments in automation and software, while macro and currency risks remain.

8 months ago - Transcripts